Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Epionce is a professional-grade cosmeceutical skincare line developed by Episciences, Inc., and founded by dermatologist Dr. Carl Thornfeldt. The brand's therapeutic philosophy is based on the Barrier Repair and Anti-Inflammatory model of skin health, which posits that most skin aging and disease states result from a compromised stratum corneum and chronic sub-clinical inflammation. Epionce products are formulated with a proprietary blend of botanical ingredients—including meadowfoam, flax, apple, and date extracts—designed to penetrate the skin barrier to deliver essential lipids (cholesterol, ceramides, and free fatty acids) and inhibit pro-inflammatory mediators. Clinical studies have demonstrated its efficacy in improving conditions such as photoaging, acne vulgaris, atopic dermatitis, and psoriasis, often performing comparably to prescription-strength topicals like tretinoin or corticosteroids with fewer side effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Epionce.